Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Tuesday, soared 0.40% from the previous trading day, before settling in for the closing price of $14.86. Within the past 52 weeks, AVDL’s price has moved between $10.25 and $19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -40.99%. The company achieved an average annual earnings per share of 74.19%. With a float of $90.35 million, this company’s outstanding shares have now reached $96.27 million.
Considering the fact that the conglomerate employs 154 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 94.62%, operating margin of -103.82%, and the pretax margin is -112.09%.
Avadel Pharmaceuticals plc (AVDL) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Avadel Pharmaceuticals plc is 6.15%, while institutional ownership is 71.93%. The most recent insider transaction that took place on Jan 16 ’24, was worth 29,000. In this transaction Chief Financial Officer of this company bought 2,000 shares at a rate of $14.50, taking the stock ownership to the 80,500 shares. Before that another transaction happened on Dec 28 ’23, when Company’s Director sold 75,000 for $14.53, making the entire transaction worth $1,089,750. This insider now owns 67,025 shares in total.
Avadel Pharmaceuticals plc (AVDL) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.41 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.37) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 74.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to 4.78% growth over the previous five years of trading.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Trading Performance Indicators
Avadel Pharmaceuticals plc (AVDL) is currently performing well based on its current performance indicators. A quick ratio of 2.52 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach 0.61 in one year’s time.
Technical Analysis of Avadel Pharmaceuticals plc (AVDL)
Compared to the last year’s volume of 1.15 million, its volume of 1.84 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 58.03%. Additionally, its Average True Range was 0.73.
During the past 100 days, Avadel Pharmaceuticals plc’s (AVDL) raw stochastic average was set at 53.72%, which indicates a significant decrease from 57.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.49% in the past 14 days, which was higher than the 44.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.66, while its 200-day Moving Average is $15.24. Nevertheless, the first resistance level for the watch stands at $15.23 in the near term. At $15.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.92. If the price goes on to break the first support level at $14.53, it is likely to go to the next support level at $14.14. Now, if the price goes above the second support level, the third support stands at $13.83.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Key Stats
Market capitalization of the company is 1.44 billion based on 96,271K outstanding shares. Right now, sales total 27,960 K and income totals -160,280 K. The company made 41,500 K in profit during its latest quarter, and -13,820 K in sales during its previous quarter.
